Teza Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Teza Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-35,579	Closed	-$267K	–	324
2025 Q1	$267K	Sell	35,579 -12,295	-26%	-$99.2K	0.12%	291
2024 Q4	$360K	Sell	47,874 -4,864	-9%	-$36.9K	0.05%	333
2024 Q3	$401K	Sell	52,738 -8,937	-14%	-$67.9K	0.04%	432
2024 Q2	$381K	Buy	61,675 +16,640	+37%	+$91.8K	0.05%	406
2024 Q1	$229K	Buy	45,035 +7,615	+20%	+$42.8K	0.03%	489
2023 Q4	$224K	Buy	37,420 +18,968	+103%	+$110K	0.04%	475
2023 Q3	$131K	Buy	18,452 +2,090	+13%	+$15K	0.02%	554
2023 Q2	$115K	Buy	+16,362	New	+$131K	0.02%	539

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Teza Capital Management's BCRX Position: Q2 2025 in Review

Teza Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 35,579 shares — an estimated $267K sold.

Teza Capital Management first reported a position in BCRX in Q2 2023 and held it in 8 quarters. The position peaked at $401K in Q3 2024. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

Teza Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Teza Capital Management sold 35,579 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $267K.
Teza Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2023 and held it in 8 quarters.
Teza Capital Management's BioCryst Pharmaceuticals position peaked at $401K in Q3 2024.
294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Teza Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.